Category Business

IQVIA

IQVIA Acquires Charles River Laboratories’ Discovery Services to Enhance Drug Discovery Capabilities

IQVIA Strengthens Early-Stage Discovery Research with Advanced In Vitro and AI-Driven Solutions Why is the life sciences industry facing a critical need for accelerated drug discovery? IQVIA Holdings Inc. a global leader in advanced analytics, technology solutions, and clinical research…

Read MoreIQVIA Acquires Charles River Laboratories’ Discovery Services to Enhance Drug Discovery Capabilities
IntraBio Inc.

IntraBio Inc. Secures Orphan Medicinal Product Designation for CACNA1A Disorders

Positive Opinion Paves Way for Phase III Trial of Acetylleucine in Rare Neurological Conditions Why are rare neurological disorders often overlooked in drug development? IntraBio Inc., an Austin, Texas-based global biopharmaceutical company, is addressing this gap by advancing a potential treatment…

Read MoreIntraBio Inc. Secures Orphan Medicinal Product Designation for CACNA1A Disorders
Gossamer

Gossamer Bio Announces Topline Results for Phase 3 PROSERA Study of Seralutinib in PAH

Gossamer Bio Reports Mixed Results for Seralutinib in PAH, Demonstrates Strong Efficacy in High-Risk Subgroups Is the current landscape of pulmonary arterial hypertension (PAH) treatments failing to meet the needs of high-risk patients? Gossamer Bio, Inc. a biopharmaceutical company focused…

Read MoreGossamer Bio Announces Topline Results for Phase 3 PROSERA Study of Seralutinib in PAH
Phase 3

Phase 3 Data Support ENTYVIO® (vedolizumab) for Pediatric Moderate to Severe Ulcerative Colitis

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis Takeda today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO® (vedolizumab) can offer…

Read MorePhase 3 Data Support ENTYVIO® (vedolizumab) for Pediatric Moderate to Severe Ulcerative Colitis
NexEos Bio

NexEos Bio Secures FDA Green Light to Progress NTX-1024 into Phase II/III Clinical Development

NexEos Bio Announces FDA Clearance of IND Application to Proceed to Phase II/III Trial of NTX-1024 in Vernal Keratoconjunctivitis NexEos Bio Vision Health a clinical-stage biopharmaceutical company developing novel therapies and diagnostics targeting eosinophil-mediated diseases, today announced that the U.S.…

Read MoreNexEos Bio Secures FDA Green Light to Progress NTX-1024 into Phase II/III Clinical Development